What's in Sumitomo Pharma Switzerland GmbH's pipeline?

Sumitomo Pharma Switzerland GmbH has 6 drugs in our index: 2 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with Sumitomo Pharma Switzerland GmbH's portfolio?

Top competitors by shared drug class: AEterna Zentaris, Assaf-Harofeh Medical Center, EMD Serono, El Shatby University Hospital for Obstetrics and Gynecology, Eugonia.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sumitomo-pharma-switzerland-gmbh.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Sumitomo Pharma Switzerland GmbH — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sumitomo Pharma Switzerland GmbH pipeline: 2 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 2 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Relugolix + Estradiol + Norethindrone Acetate	Relugolix + Estradiol + Norethindrone Acetate	marketed	GnRH antagonist combination with hormone replacement therapy	GnRH receptor (relugolix component)	Gynecology / Endometriosis
Cultured Thymus Tissue	Cultured Thymus Tissue	marketed	Thymic extract/cultured tissue immunotherapy		Immunology
Relugolix Combination Tablet	Relugolix Combination Tablet	phase 3	GnRH receptor antagonist	GnRH receptor	Oncology
Relugolix Combination Therapy	Relugolix Combination Therapy	phase 3	GnRH antagonist	GnRH receptor	Oncology

Therapeutic area mix

Oncology · 2
Gynecology / Endometriosis · 1
Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AEterna Zentaris · 1 shared drug class
Assaf-Harofeh Medical Center · 1 shared drug class
EMD Serono · 1 shared drug class
El Shatby University Hospital for Obstetrics and Gynecology · 1 shared drug class
Eugonia · 1 shared drug class
Instituto Valenciano de Infertilidad, IVI VALENCIA · 1 shared drug class
Instituto de Investigacion Sanitaria La Fe · 1 shared drug class
Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sumitomo Pharma Switzerland GmbH:

Cite this brief

Drug Landscape (2026). Sumitomo Pharma Switzerland GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sumitomo-pharma-switzerland-gmbh. Accessed 2026-05-17.